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Opioids are widely used to treat acute and chronic pain. But opioid addiction to 
these compounds can cause social and life-threatening health problems, including the risk 
of overdose. In this thesis, I evaluated IBNtxA (3-iodobenzoyl naltrexamine), a novel μ 
opioid receptor (MOR) agonist structurally related to the classical MOR antagonist 
naltrexone, in drug discrimination studies in order to better understand its subjective effects 
and more thoroughly its abuse liability. IBNtxA represents an intriguing lead compound 
for preclinical drug development specifically targeting MOR splice variants, potentially 
creating effective analgesics with reduced side effects. These results indicate that IBNtxA 
produces potent antinociception and has low abuse liability, likely driven by substantial κ 
opioid receptor agonist signaling effects. I also evaluated whether a combination of drugs 
can produce synergistic antinociceptive effects. Using von Frey testing and hot plate 
procedures, I measured the antinociceptive effects of morphine, the novel α2/α3 subunit-
containing GABAA receptor positive allosteric modulator MP-III-024, and their 
combination. Combinations of morphine and MP-III-024 produced supra-additive effects 
in both assays, indicating some level of synergy from these compounds. Results from these 
studies may lead to the development of new analgesic treatments with improved side-effect 
profiles, including reduced abuse liability. 
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1.1. History of Opioids 
Opium is an ancient drug derived from the milky sap of the opium poppy and used for 
medicinal purposes. (Booth, 1986) The use of raw opium in the modern era has been 
supplanted by more specific preparations of opiates—the naturally occurring compounds 
in opium—and by semisynthetic and synthetic opioids. There are several clinical effects of 
opioids, but it their most significant effects involve relieving pain. (National Institute of 
Diabetes and Digestive and Kidney Diseases; 2012)  
Around 3400 B.C. in lower Mesopotamia, the opium poppy was first cultivated. This 
poppy juice was known to produce euphoric effects, so Sumerians called it “Hul Gil” or 
“the Joy Plant”. (Schiff, 2002) After that, opium was cultivated in ancient Egypt around 
1300 B.C. An Egyptian medical document called the Ebers Papyrus describes that poppy 
grains used to stop a crying child from crying at once. (Brownstein, 1993) At that time, 
opium was widely cultivated, traded, smoked, and used medically throughout the ancient 
world to every major civilization in Europe and Asia. It was used to treat pain and many 
other ailments successfully. (Schiff, 2002; Askitopoulou et.al., 2002; Booth, 1986; Dikötter 
et al., 2004). An ancient Greek physician, Hippocrates, described that for treating pain, 
internal diseases and epidemics, opium is an effective choice of drug. He also mentioned 
that the mixture of white poppy juice and the seed of nettle work as a narcotic, hypnotic 
and cathartic drug. (Kleisiaris, et. al., 2014) 
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In 1806, the German scientist Friedrich Wilhelm Adam Sertürner dissolved opium into 
acid and then neutralized it with ammonia. This allowed him to identify the primary active 
ingredient, a weak base or alkaloid called Principium somniferum or morphine. 
(Brownstein, 1993; Krishnamurti & Rao, 2016)) This is the first time they got a safe and 
effective way to treat pain and that is why Sir William Osler called this God’s own 
medicine. (Young, 2007; Batmanabane, (2014) Morphine was taken orally until the 
invention of the hypodermic needle by the Scottish physician Charles Wood allowed the 
use of morphine injections to relieve neuralgia-induced pain. (Rosenblum et. al., 2009) 
German physician Edward Livenstein described addiction, withdrawal syndrome, relapse 
and explained that craving for Morphine was basically a physiological response. 
(Rosenblum et. al., 2009)   In 1874, heroin (diacetylmorphine) was first synthesized by the 
English researcher C.R. Wright. (Merry 1975) Heroin is less addictive than morphine with 
higher efficacy. (Rosenblum et. al., 2009)  
The term “opioid” originated in 1950, proposed by George Acheson, and means opiate-
like—a combination of the word opium and the suffix –oid, meaning “like” or “resembling. 
(Eades et al., 1963) Opioid drugs have structural similarities with morphine but are either 
synthetic or semisynthetic. (Martin, 1983) The endogenous (i.e., naturally occurring) 
opioid peptides, endorphins, were first discovered in 1974 by two independent group of 
investigators—John Hughes and Hans Kosterlitz of Scotland, and Rabi Simantov and 





1.2. Classifications of Opioid Drugs 
Opioid drugs have a broad spectrum of activity. According to their procedure of 
synthesis, clinical opioids can be classified into three groups: 
1. Natural Opioids: Extracted directly from poppy seeds, such as morphine, papaverine, and 
codeine. 
2. Semi-synthetic Opioids: Obtained by the modifications of natural compounds, including 
morphine esters such as heroin, oxycodone, and oxymorphone. 
3. Fully synthetic compounds, such as pethidine, fentanyl, and tramadol. (Jamison & Mao, 
2015; Pathan & Williams, 2012) 
Based on their binding affinity and effects on the four major opioid receptors, Opioids can 
also be classified into four types: 
1. The δ-opioid receptor (DOR); 
2. The κ-opioid receptor (KOR); 
3. The μ-opioid receptor (MOR); 
4. The nociception/orphanin opioid receptor (NOP). 
Opioids can also be classified based on their signaling properties: 
1. Full agonists: These activate the opioid receptors in the brain fully getting the full opioid 
effect (e.g., morphine, etorphine, methadone, meperidine, codeine, hydromorphone, 
codeine, fentanyl, heroin, hydrocodone, oxycodone, oxymorphone) 
2. Partial agonists: These partially activate opioid receptors (e.g., buprenorphine, 
butorphanol, tramadol, pentazocine, nalbuphine) 
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3. Antagonists: These block the activity of agonists and partial agonists (e.g., naloxone, 
naltrexone). (Jamison & Mao, 2015; Waldhoer et al., 2004) 
There are some opioid peptides which produced by the body itself called endogenous 
opioids or endogenous ligands. These are not like the regular clinical opioids. For 
producing pharmacological actions, these endogenous opioids need to bind to the opioid 
receptors. (Li et al., 2012; Waldhoer et al., 2004). Though there are numerous known 
endogenous opioid peptides, they can be classified into three different groups of ligands—
enkephalins, endorphins, and dynorphins—which usually signal through the three major 
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1.3. Molecular Targets of Opioids 
Opioid receptors belong to the super-family of G protein-coupled receptors 
(GPCRs) which are the most abundant class of cell-surface receptors in the central nervous 
system. (Mansour et al., 1993; Vortherms, & Roth, 2005) The presence of opioid receptors 
is high in the central nervous system (CNS), but they are found in many peripheral tissues 
like the tissue of small intestine, large intestine, adrenal, kidney, lung, spleen, testis, ovary 
and uterus of the mammalian groups of organism. (Wittert et al., 1996) Opioids have their 
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action at a cellular level, activating opioid receptors distributed throughout the CNS. The 
concentrations of opioid receptors are high in different areas of CNS, including the nuclei 
of tractus solitarius, periaqueductal grey, cerebral cortex, thalamus, and the substantia 
gelatinosa of the spinal cord. (Henriksen, & Willoch, 2008) 
Three major subtypes of opioid receptors have been identified: Delta (δ), Mu (µ) 
and Kappa (κ) opioid receptors. Endogenous peptides like endomorphines, enkephalins, 
dynorphins, naturally occurring alkaloids, and other semisynthetic and synthetic small 
molecule ligands activate these receptors. (McCurdy et al., 2003) Another receptor 
subtype, called the nociception opioid receptor (NOP receptor), is phylogenetically related 
to other three, but it does not bind the same ligands. (Shang, & Filizola, 2015) 
Delta (δ) opioid receptors (DORs) are mainly located in the brain, particularly in 
neural areas involved with olfaction and motor integration. (Mansour et al., 1988) DOR 
signaling is responsible for spinal, supraspinal analgesia and reduce gastric motility. 
(Trescot et al., 2008) Delta agonists and antagonists has anxiolytic activity of the opioid 
tone facilitated by DOR. (Saitoh et al., 2005; Perrine et al., 2006) DORs are a G protein-
coupled receptor that respond to enkephalins as endogenous ligands. (Hart et al., 1985; 
Quock et al., 1999) Based on receptor binding studies, endogenous opioids have greater 
selectivity for δ-opioid receptor (DOR) over clinical opioids. DORs are mainly existing in 
pontine nuclei, amygdala and olfactory bulbs of CNS. Primarily the DOR is responsible 
for analgesia, physical dependence, euphoria, convulsant, and antidepressant effects. 
(Chung & Kieffer, 2013; Mao, 1999). 
Mu (µ) opioid receptors (MORs) are located mostly presynaptically in the 
periaqueductal gray region, and in the superficial dorsal horn of the spinal cord. MORs are 
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also found in the external plexiform layer of the olfactory bulb, the nucleus accumbens, 
layers of the cerebral cortex, nuclei of the amygdala, intestinal tract, and the nucleus of the 
solitary tract. 
MORs are responsible for different physical conditions related to supraspinal 
analgesia, respiratory depression, euphoria, sedation, decreased gastrointestinal motility, 
and physical dependence. (Benyamin et al., 2008) Three different MOR subtypes, µ1, µ2, 
and µ3, are known. These are not separate genes; they are splice variants of a single gene. 
(Cadet, 2004) µ1 is associated with analgesia, euphoria, and serenity. µ2 is associated with 
respiratory depression, pruritus, prolactin release, physical dependence, euphoria, reduced 
gastrointestinal motility, miosis and sedation. (Pasternak et al., 2013) µ3 is associated with 
vasodilation. (Mao, 1999; Stein et al., 2003) 
κ opioid receptors (KORs) are mainly present in the substantia gelatinosa, 
hypothalamus, periaqueductal gray, and claustrum in the brain. KOR activation is 
responsible for producing spinal analgesia, sedation, miosis, dysphoria, neuroprotection, 
and diuresis. There are three different subtypes of KOR, namely κ1, κ2 and κ3. (Lalanne et 
al., 2014; Stein et al., 2003) 
The natural ligand of the nociceptin opioid receptor (NOP) is the 17 amino acid 
neuropeptides known as nociceptin (N/OFQ) (Malmberget al., 1997). The expression of 
this receptor mainly in cortex, ventral forebrain, hippocampus, hypothalamus, amygdala, 
and in the dorsal horn of spinal cord. (Donica et al., 2013; Koob et al., 2014). NOP 
activation produces physiological responses such as anxiety, food intake, learning, 
locomotor etc. can be produced. (Donica et al., 2013) 
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Table 2  
Different Opioid Ligands and Receptor Targets  
         Note. This information is adapted from Lemberg et al., 2008; Kumar et al., 2019;   

















β-endorphin +++ +++ +++ - 
Leu-enkephalins + - + - 
Dynorphin A & B ++ +++ + + 
Nociceptin/orphanin FQ - - - +++ 
Clinical and Nonclinical Ligands 
Agonists 
Morphine +++ + + - 
Diamorphine +++ + + - 
Fentanyl +++ + - - 
Pethidine +++ + + - 
Partial Agonists 
Buprenorphine ++ + - - 
Pentazocine - ++ - - 
Antagonists 
Naloxone +++ ++ ++ - 
Naltrexone +++ ++ ++ - 
+ = low affinity, ++ = moderate affinity, +++ = high affinity, - = no affinity 
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1.4. Mechanism of Action of Opioid Agonists 
Generally, pain sensations are signaled by primary sensory neurons releasing 
predominantly substance P and glutamate in the dorsal horn of the spinal cord. 
Spinothalamic tracts help to transmit nociceptive information to the brain. The activation 
of descending pathways depends on the ascending information. This ascending information 
can trigger the descending pathways, from the midbrain periaqueductal grey area, which 
exercise an inhibitory control over the dorsal horn. (Ossipov et al., 2014) 
Opioid activation of opioid receptors produces intracellular signaling effects typical 
of Gαi/o-coupled GPCRs. Initially, guanosine triphosphate (GTP) binds with the Gα subunit 
and GTP converts into the guanosine diphosphate (GDP). GDP generates α-GTP complex 
to dissociate away from the βγ complex. (Pathan & Williams, 2012; McDonald & Lambert, 
2005; Stein, 2016). The available free α-GTP and βγ interact with separate target proteins. 
As a result, inhibition of adenylate cyclase happened as well as cyclic adenosine 
monophosphate (cAMP) decreases inside the cell. (McDonald & Lambert, 2005; Pathan & 
Williams, 2012). 
With respect to synaptic signaling, opioids can act at two different sites, the presynaptic 
nerve terminal, and the postsynaptic neuron. The postsynaptic actions of opioids are 
normally inhibitory whereas the presynaptic action of opioids is to inhibit neurotransmitter 
release. Inhibition of the neurotransmitter release is their major effect in the nervous 
system. Neurotransmitter release from neurons is normally preceded by depolarization of 
the nerve terminal and Ca2+ entry through voltage sensitive Ca2+ channels are the process 
to release Neurotransmitter from neurons. Opioids have direct effects on Ca2+ channels to 
reduce Ca2+ entry or on increasing the outward K+ current and thus the inhibition of 
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neurotransmitter release happened. As a result, repolarization time and the duration of the 
action potential becomes lower. Opioids has both effects because opioid receptors are 
ostensibly coupled via G-proteins straight to K+ channels and voltage-sensitive Ca2+ 
channels. All MOR, DOR, and KOR signaling can also regulate Ca2+ channels in both pre- 
and post-synapse reduces Ca2+ inside the cell and impaired the neurons’ excitability. 
(Simons, 1988; Stein, 2016) These intercellular events cause hyperpolarization as well as 
hinder neuronal firing in key nociceptive circuits. As a result, it eventually reduces pain. 
(McDonald & Lambert, 2005; Pathan & Williams, 2012; Simons, 1988; Stein, 2016) 
1.5. Use of Opioid Drugs 
1.5.1. As analgesics. Opioids are very effective drugs for the treatment of pain. The 
management of acute severe pain and chronic pain is completely depending on the opioid 
analgesics. A lot of people are suffering from the chronic pain all over the world. In just 
the United States, more than 100 million peoples are suffering from acute and chronic pain 
and around 6-8 million undergo long-term treatment by opioid drugs. (Jamison & Mao, 
2015; Kalso et al., 2004). Opioid analgesics work effectively against both cancer and non-
cancer pain. There is a significant effect of intravenous infusion of opioid analgesics to 
heal the neuropathic pain like central pain, postherpetic neuralgia and mixed neuropathic 
pain. Different doses of oral opioids are effective against neuropathic, musculoskeletal, and 
other non-cancer pain. (Kalso et al., 2004). WHO confirmed the effectiveness of opioid 
drugs to manage the most challenging cancer pain. Almost 75% of the cancer pain managed 
by applying opioid analgesics. (Thapa et al., 2011). Morphine is enough alone to manage 
severe cancer pain of almost 85% of patient. It is like a single pharmacotherapy. 
Combination therapy with morphine and other analgesic can provide synergistic effects. 
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(Gilson et al., 2004). These opioid analgesics are very effective against cancer pain like 
severe pain but due to some abusive properties which make it intricate. (Thapa et al., 2011) 
1.5.2. Treatment options for pulmonary edema. Opioids, especially morphine, have 
been used for a long time to treat pulmonary edema. In pulmonary edema, a patient’s left 
ventricle fails to properly operate, leading to elevated hydrostatic pressure and increased 
pulmonary circulation. As a result, extra fluid accumulates in the interstitium and alveoli 
of the lungs. (Ellingsrud & Agewall, 2016) To treat pulmonary edema, reduction of 
hydrostatic pressure through lowering preload and afterload is required and can be 
achieved by using the vasodilatory properties of morphine. (Mattu et al., 2005) 
1.5.3. Treatment options for diarrhea. Opioid drugs can be used to treat irritable 
bowel syndrome with diarrhea (IBS-D). There is no effective treatment method is available 
to treat IBS-D, so opioids can be a treatment of choice. A Schedule IV drug called 
eluxadoline was approved by the FDA to manage IBS-D and features a mixed 
pharmacology: it is a MOR agonist, which has both DOR antagonist activity and KOR 
agonist activity. Eluxadoline, provides relief of IBS-D-associated symptoms with 
significantly lower side effects, specifically constipation, by targeting the local opioid 
receptors in the gut, which reduces the side effects of the central nervous system. (Maltz & 
Fidler, 2017) 
1.5.4. As a cough suppressant. Codeine and hydrocodone have been used in cough 
medications along with other drugs like chlorpheniramine (an antihistamine), 
pseudoephedrine (a decongestant), and guaifenesin (an expectorant). Some studies show 
that codeine does not have any significant effect on chronic obstructive pulmonary disease 
(COPD) in adults or on acute cough in children. The United States Food & Drug 
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Administration (FDA) does not recommend cough medication with opioids if the patient 
is younger than 18 years. (Smith et al., 2006; McCrory et al., 2013) 
1.5.5.  As an anesthetic. There are some available narcotic analgesic opioids, 
especially morphine, used as anesthetic agents. In particular, for patients with 
cardiovascular disorders, opioids are used in different major surgeries to prevent the 
occurrence of cardiac depression. (Bovill et al., 1984; Hug, 1992) 
1.6. Adverse Effects of Opioids 
Opioids undoubtedly are effective analgesics, but they have well-known side effects that 
include respiratory depression, sedation, constipation, bradycardia, tolerance, 
hyperalgesia, dependence, immunologic effects, hormonal change, sleep disturbances, and 
abuse and addiction. (Ballantyne & Mao 2003; DeWire et al., 2013) 
Opioid analgesia in patients can be difficult to manage because of risks associated with 
tolerance, hyperalgesia, withdrawals symptoms and dependency, euphoria and drug abuse, 
and opioid addiction. (Fields & Margolis, 2015; Jamison & Mao, 2015; Volkow & 
McLellan, 2016) 
1.6.1. Respiratory depression. For survival, humans are totally dependent on the 
cardiorespiratory or ventilatory control system for adequate uptake of oxygen and removal 
of CO2 using lungs. (Dahan et al., 2010) Potent opioid analgesics depress ventilation by 
acting on μ-opioid receptor (MOR) located on respiratory neurons in the brainstem. This 
potentially life-threatening cause of substantial morbidity and mortality called opioid-
induced respiratory depression (OIRD) (Van der Schier et al., 2014; Dahan et al., 2010) 
OIRD initiates cardiorespiratory arrest with subsequent hypoxia and hypercapnia, resulting 
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fatalities. (Dahan et al., 2010; Morgan et al., 2006; Oderda et al., 2007; Oderda et al., 2013) 
Opioid receptors expressed abundantly in the CNS specifically respiratory neurons which 
is directly related to OIRD. (Pattinson, 2008)Though some cases of opioid-induced 
respiratory depression acts as a beneficial for pain patients, but ultimately it may increase 
the mortality if the opioid addicts take similar dose in different condition or relapse after a 
period of abstinence. (Siegel et al., 1982) 
1.6.2. Opioid-induced sedation. Opioids produce sedation and drowsiness, 
primarily via anticholinergic and other multiple inhibitory effects on cerebral activity. 
(Ahmedzai, 1997; Slatkin & Rhiner, 2004)) Available treatments for opioid-induced 
sedation include methylphenidate. For cancer patients, administrating 10-15 mg doses of 
methylphenidate reduced drowsiness significantly. Concurrently, reduction of opioid doses 
without increasing pain may be possible. (Wilwerding et al., 1995) While other available 
treatment options for treating sedation include dextroamphetamine, donepezil, modafinil 
and caffeine, methylphenidate is considered the first-line therapy because of its low side 
effects and abuse potential. (Reissig & Rybarczyk, 2005) Opioids cause central nervous 
system depression, which can diminish a patient’s ability to operate heavy equipment and 
drive vehicles. A patient should be able to operate a vehicle after the opioid analgesic 
regimen reaches a stable condition and patient doesn’t have any significant cognitive 
impairments. (Trescot et al., 2008) One study showed that a group of patients receiving 
opioid analgesic for chronic pain, they are capable to operate vehicles during daytime. 
(Cotsonis, 2005) Another study recommended that with stable doses of opioids, patients 




1.6.3. Opioid-induced constipation. Opioid-induced constipation (OIC) is a 
common problem during opioid administration, even with the single dose. The main cause 
of constipation is interaction of a plethora of underlying pathophysiologies, lifestyle 
factors, and medications which leads to opioid-induced bowel dysfunction. (McMillan, 
2004) Chronic constipation may be caused of haemorrhoid formation, rectal pain and 
burning, bowel obstruction, bowel rupture, upper gut dysfunctions, including 
gastroesophageal reflux disease and death. (Ricardo Buenaventura et al., 2008; Holzer, 
2004)40-95% patients are facing this problem and resulting a significant increase of 
morbidity and mortality after long-term consequences of constipations. (Datta et al., 2008; 
Sizar, Gupta, 2019) In the GI tract, opioid drugs prevent gastric emptying and peristalsis. 
As a result, delayed absorption of medications and increased absorption of fluid happened. 
The lack of fluid in the intestine is the cause to hardening of stool and constipation. (Sizar, 
Gupta, 2019) In severe condition of constipation, reduction of opioid dose required 
resulting in reduced activity of analgesia. In chronic condition hemorrhoid, rectal pain and 
burning sensation, bowel obstruction, potential bowel rupture and death can be happened. 
(Datta et al., 2008) This is not clear that this type of constipation in human is centrally or 
peripherally mediated. Morphine-induced constipation mediated within the CNS and alter 
autonomic outflow to the gut. (Yuan, Foss, 2000) Also, it affects intestinal motility 
peripherally by a direct stimulation of opioid receptors in the enteric nervous system. 
(Sternini 2001) The management of opioid induced constipation is not an easy task. 
Opioids can be administrating after carefully considering the risk -benefit ratio or taking 
some alternative options such as Lifestyle modification, alteration of aggravating factors 
and/or the use of simple laxatives. (Bharucha et al. 2016) 
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1.6.4. Opioid-induced bradycardia. Opioids mainly binds to the opioid-specific 
receptors specially in central nervous system (CNS), but opioid specific receptors also 
found in other different organs like cardiovascular tissue. (Chen, & Ashburn, 2015; 
Warltier et al., 2000) When opioid administered as an anesthetic agent alone, it produces 
some effect on heart but do not depress cardiac contractility except the high doses of 
meperidine. (Chen, & Ashburn, 2015; Warltier et al., 2000) If opioids are combined with 
other medications, there are significant changes in cardiac function: it impacts the 
cardiovascular system including vagus nerve-mediated bradycardia. (McIntosh et al., 1992; 
Lessa & Tibiriçá, 2006; Chen, & Ashburn, 2015) Patients may face vasodilation and 
decreased sympathetic tone after acute administration of opioids. If given concurrently 
with the benzodiazepines, leads to decrease cardiac output significantly. Opioids like 
morphine, hydromorphone, hydrocodone, and meperidine can cause significant decreases 
in systemic vascular resistance and blood pressure by releasing histamine. But there are no 
effects on intraoperative ischemia, postoperative myocardial infarction or causing death of 
opioid-based anesthetics use. (Chen, & Ashburn, 2015; Fareed et al., 2013) 
1.6.5. Opioid tolerance. Opioids are well-established to induce tolerance, 
described as the decreased efficacy of an opioid agonist after repeated or prolonged 
administration of a specific dose. (Morgan, & Christie, 2011). Drug interactions with 
opioid receptor(s), dose of drug and frequency of drug administration are the considerable 
factors for the development and extent of the tolerance. There are several reasons opioid 
tolerance develops, including upregulation of drug metabolism, desensitization of receptor 
signaling, and downregulation of receptors. (Cahill et al., 2016) Opioid-induced tolerance 
is problematic and challenging to manage. Hospitalized patients require longer hospital 
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stays, have higher readmission rates, and have higher mortality rates. (Gulur et. al., 2014) 
Increased opioid doses given to counter tolerance can result in opioid-induced 
hyperalgesia. (Cahill et al., 2016) 
1.6.6. Opioid-induced hyperalgesia. Opioid-induced hyperalgesia (OIH) is 
defined as a state of increased pain sensitivity following the long-term use of high-dose 
opioids and occurs when neoplastic modifications happen in both peripheral and central 
nervous system. (Lee et al., 2011, Tompkins & Campbell, 2011). The molecular 
mechanisms that cause OIH are not well-established yet, but there are several proposed 
mechanisms. OIH may result when tolerance develops by molecular adaptations in MOR-
expressing neurons that can change the interactions between cells and activate the 
independent oppositional system. (Zeng et al., 2006; Vera-Portocarrero et al., 2007) 
Opioid-induced cell apoptosis may contribute to the development of hyperalgesia; in 
particular, loss of GABA neurons via apoptosis may lead to changes in spinal neuron 
circuits. (Mao et al., 2002) This sensitization is a paradoxical response and patients become 
more sensitive to certain painful stimuli during the opioid treatment. The pain experienced 
in OIH can be very similar to the patient’s original pain. OIH shows a distinct, definable, 
and characteristic phenomenon that can prove about the loss of opioid efficacy in some 
patients. (Lee et al., 2011; Tompkins & Campbell, 2011)  
1.6.7. Opioid withdrawal and dependence. Opioid treatments can result in 
withdrawal symptoms, including the development of an altered physiological state 
involving autonomic and somatic hyperactivity. Dependence is a physical state that occurs 
during withdrawal following repeated administration of opioid drugs, producing persistent 
physical–somatic withdrawal symptoms. (Higgins et al., 2018) In general, physical 
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dependence produces a disorder in which the patient is not able to reduce or quit opioid use 
because withdrawal symptoms become too severe. (Collett, 1998) Importantly, physical 
dependence can result in greater long-term opioid use and can lead to addiction. 
1.6.8. Opioid-induced immunologic effects. In the 1980s, scientists demonstrated 
cellular immune suppression and decreased resistance to bacterial infection in guinea pigs 
after administrating morphine. Opioids increased the incidence of infections in heroin 
addicts and act as a cofactor in the pathogenesis of human immunodeficiency virus. While 
some exogenous opioids can generate immunosuppression, their endogenous counterparts 
like endorphins induce immune activation. (Stephanou et al., 1991; Cantacuzene, 1898) 
Immunosuppression leads by opioids have different mechanisms which produce different 
immune profile. Codeine, methadone, morphine, fentanyl, sufentanil, and remifentanil 
produce strong immunomodulating effect whereas oxycodone, tramadol, buprenorphine 
and hydromorphone produce weak immunomodulating effect. Morphine regulates 
adaptive and innate cells, like NK cells, macrophages, mast cells, B cells and T cells. 
Additionally, morphine’s action is connected to central nervous system structures and the 
HPA axis suppressed NK cell cytotoxicity and lymphoproliferation. (Haroutounian, 2018) 
The lowest immunosuppressive agent is buprenorphine which considered as a first-line 
analgesic. (Davis, 2012) Since acute and chronic opioid administration can be a reason of 
the inhibitory effects on antibody and cellular immune responses, natural killer cell 
activity, cytokine expression, and phagocytic activity. The immunologic effects of opioids 
are controlled by central and peripheral mechanisms. (Stephanou et al., 1991; Peterson et 
al., 1998; Chuang et al. 1995) Central opioid receptors can facilitate peripheral 
immunosuppression by involving the hypothalamic- pituitary-adrenal axis and the 
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autonomic nervous system. Peripheral immune cells under the effect of cytokines, can 
release endogenous opioids modulating analgesia and inflammatory responses. (Chuang et 
al. 1995; Trescot et al., 2008) 
1.6.9. Opioid-induced hormonal changes. Opioid administration produces 
hormonal effects in both men and women. These effects on hormonal function, called 
opioid endocrinopathy (OE), also occurs when the serum hormone levels return to normal 
after drug withdrawal. (Trescot et al., 2008) Opioids can affect different hormones, 
including testosterone, estrogen, luteinizing hormone, gonadotrophin releasing hormone, 
dehydroepiandrosterone and dehydroepiandrosterone sulfates, adrenocorticotropin and 
corticotropin-releasing hormone, and cortisol. Sexual disorders such as erectile 
dysfunction and decreased libido, depression, and decreased energy levels are common 
adverse effects for men. (Datta et al., 2008) One to four hours after acute administration of 
opioids, testosterone levels are significantly lowered, and it takes around 24 hours to return 
to normal levels. (Daniell, 2002) When opioids are administered chronically, it results in 
tonic decreases in both total and free testosterone levels. (Datta et al., 2008) There are other 
similar hormonal side effects for women, including depression, dysmenorrhea, sexual 
dysfunction, and potentially reduced bone mineral density. (Daniell, 2008) 
1.6.10. Opioid-induced sleep disturbances. Opioid-related sleep disturbances 
include disorders of initiating and maintaining sleep, disorders of excessive somnolence, 
disorders of sleep–wake schedule, and dysfunctions associated with sleep, sleep stages, or 
partial arousals. (Walker et al., 1990) These disturbances are commonly experienced by 
cancer patients. (Moore & Dimsdale, 2002) While sleep disturbances can result from 
insomnia or pain, there is no evidence correlating pain severity and sleep disturbances. 
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(Trescot et al., 2008) There is some evidence that opioids can increase the number of sleep-
wake transitions, reducing total sleep time and efficacy. (Koren et al., 2006; Kurz & 
Sessler, 2003) There are many neurotransmitters that regulate sleep and waking, including 
noradrenaline, serotonin, acetylcholine, dopamine, histamine, gamma-aminobutyric acid 
(GABA), the pituitary hormones, and the neurohormone melatonin. Drugs that can alter 
signaling by these neurotransmitters can affect sleep. Opioid drugs can alter the balance of 
these neurotransmitters, but how opioids exactly disrupt the sleep is still unclear. (Trescot 
et al., 2008) 
1.6.11. Opioid abuse and addiction. Opioid addiction is a chronic, relapsing 
disorder characterized by a strong and habitual desire to use opioid drugs when medically 
unnecessarily. People can become addicted even when administered opioid drugs as 
prescribed, because opioids have very high possibility for causing addiction. (Morgan, & 
Christie, 2011). Opioids are neuroactive substances that alter neurotransmitter functions, 
inducing positive changes in mood (euphoria) or reducing negative dysphoric moods. 
(Lankenau, 2002). Opioid-induced euphoria can lead to misuse and abuse of medications. 
Prolonged use of these substances leads to tolerance, physical dependence, sensitization, 
craving, and relapse. (Leshner, 1997) 
1.7. The “Opioid Epidemic” 
The “opioid epidemic” is a major public health concern arising from the over-
prescription of opioids for relieving pain and the growth in use, abuse, and overdose of 
opioids, significantly impacting patient health and economy. This opioid epidemic is not 
the first drug crisis in US: over a century ago, doctors frequently prescribed morphine to 
their patients to alleviate pain, causing the first opiate epidemic. (Courtright, 2001) 
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According to the Centers for Disease Control and Prevention, there are three different 
waves in the modern American opioid epidemic can be considered for rising the death of 
opioid overdose. The first wave started in the 1990s, when the opioid prescribing increased 
gradually. The second wave is marked by increased overdose deaths involving heroin in 
2010. The third wave began in 2013 due to significant increases in overdose deaths 
involving synthetic opioids–mainly those involving illicitly manufactured fentanyl (IMF). 
The IMF market has changed over time. IMF can also be found in combination with heroin, 
counterfeit pills, and cocaine. (Centers for Disease Control and Prevention, 2018) 
In 2016, 11.5 million Americans were misusing opioid prescriptions, more than 2.1 
million had a diagnosable opioid use disorder, and more than 42,000 people died from 
opioid overdoses. (Department of Health and Human Services, 2018) The US Department 
of Health and Human Services declared a public health emergency for this opioid crisis in 
October 2017. (US Department of Health and Human Services, 2017) Over the last two 
decades, hundreds of thousands of lives have been lost and millions more people and their 
families affected by opioid epidemic. The use of opioids is important for pain management 
but must be weighed against the costs of opioid use disorder and deaths. The CDC has 
taken actions to raise awareness and reduce the practices of opioid prescription. In 2016, 
the Comprehensive Addiction and Recovery Act (CARA) was signed into law, consisting 
of six pillars to overcome the opioid crisis: prevention, treatment, recovery, law 
enforcement, criminal justice reform, and overdose reversal. (Florence et al., 2016; CARA, 
2018) 
Opioid misuse, abuse, and overdose deaths are increasing US as well as the whole 
world. These increases started in the late 1990s and accelerated since. According to the 
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Centers for Disease Control and Prevention (CDC), the age-adjusted rate of overdose 
deaths nationally rose by 9.6% from 2016 (19.8 per 100,000) to 2017 (21.7 per 100,000). 
Opioids were involved in 70,000 overdose deaths nationally in 2017. This number 
represents 67.8% of all drug overdose deaths in the United States. Synthetic opioids are 
primarily responsible for current drug overdose-related deaths. (CDC, 2019) 
1.8. Treatments for Addiction 
Treatment options of opioid addiction are limited. Behavioral therapy and 
pharmacotherapy can be used either in individually or combination (Carroll & Onken, 
2005), but treatments combining medication along with counseling and support lead to 
improved recovery (Eitan et al., 2017). Treatment can be started with counseling, opioid 
replacement therapy, and gradual discontinuation of the drug. Discontinuation of the drug 
to quickly can produce serous a withdrawal syndrome. For managing that situation, drug 
detoxification is the option for the physicians (NIDA, 2020).  
1.8.1. Behavioral therapies. Behavioral therapy includes support for people to 
give up drugs of abuse by offering them incentives to stay away from those abusive 
compounds (Petry & Carroll, 2013; Tuten, 2012). There are several different types of 
behavioral therapies available for addiction treatment, including cognitive behavioral 
therapy, contingency management, community reinforcement approach, and motivational 
enhancement therapy (Carroll & Onken, 2005; NIDA, 2020). 
1.8.1.1. Cognitive behavioral therapy. The main goal of Cognitive-Behavioral 
Therapy (CBT) is to move the patient towards abstinence; its effects are durable and 
improve after the end of treatment (Carroll et al., 1994; Carroll et al., 2000). The focus of 
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this therapy is on relapse prevention, countering the maladaptive behavioral patterns that 
underlie substance abuse. Patients learn different skills to identify and correct the 
problematic behaviors. Eventually, those skills can be effective to stop drug abuse and 
other related problems (NIDA 2020; Carroll & Onken, 2005). Computer-based CBT 
systems are under development to treat drug abuse-related complications broadly (Carroll 
et al., 2008). 
1.8.1.2. Contingency management interventions/motivational incentives. 
Contingency management (CM) is an effective treatment approach in which patients 
receive rewards to stop taking drugs (McGovern & Carroll, 2003). There are two kinds of 
CM: voucher-based reinforcement and prize incentives CM. In voucher-based 
reinforcement, the patient receives incentive vouchers upon confirming a drug-free urine 
sample. Initially they receive low base amount of incentives, but it increases by confirming 
drug free urine sample for consecutive tests. Positive urine samples require the patient to 
start over from the baseline low incentives. Vouchers can be used for buying food items, 
movie tickets, or other items for leading healthy life. (Bickel et al., 1997; NIDA 2020) The 
program prize incentives CM provides cash prizes instead of vouchers. If participants test 
negative for drugs in urine or breath weekly for at least three months, and attend counseling 
sessions and target activities, they can win $1-100 prizes by raffle draw (Bickel et al., 1997; 
NIDA 2020). A significant number of patients have remained abstinent from opioids or 
cocaine through this CM service (Petry et al., 2005; Prendergast et al., 2006). 
1.8.1.3. Community reinforcement approach. The community reinforcement 
approach is a psychosocial intervention that includes recreational, familial, social, and 
vocational reinforcers with material incentives. These activities reinforce a non-drug-using 
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lifestyle and the goal of the treatment includes habituating the patient to a drug-free life 
(NIDA, 2020). This approach enhances the importance of family relationships, developing 
different skills, new recreational activities, and social networks. The computer-based 
version of the community reinforcement approach is effective for opioids and/or cocaine-
dependent patients (Higgins et al., 2003; NIDA, 2020). This computer-based version is 
also effective for adolescents (Brooks et al., 2010). 
1.8.1.4.  Motivational enhancement therapy (MET). This therapy is based on 
counseling to reinforce lifestyle alterations and reduced drug use. The purpose of this 
therapy is to induce rapid and internal motivational change in the patient and encourage 
abstinence. Individual sessions include an initial assessment battery session, stimulating 
discussion session, two to four individual treatment sessions, and motivational interviews. 
The principle of this interview is to build up strength to give up the abusive drugs (NIDA, 
2020; Ball et al., 2007). 
1.8.2. Addiction pharmacotherapy. Pharmacotherapy is an important step for 
treating opioid addiction, providing a beneficial effect when applied concurrently with 
behavioral therapy. Two general treatment patterns are available, opioid maintenance and 
detoxification (Stotts et al., 2009). 
1.8.2.1. Methadone. Methadone is a well-established option for opioid 
maintenance pharmacotherapy, used all over the world with a long track record (Kreek et 
al., 2010; Mattick et al., 2009). Treatment with methadone provides significantly higher 
rates of treatment retention and lower rates of illicit opioid use compared with placebo or 
no treatment (Mattick et al., 2009). Methadone is a potent analgesic and it has a good oral 
bioavailability (75%). Though methadone is an opioid agonist, it has some dissimilarities 
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with the other available opioid analgesics. Oral methadone has a longer half-life than 
heroin—this is one reason for using this as an opioid replacement (Stotts et al, 2009). There 
are some limitations of methadone for patients with chronic renal diseases and pregnant 
women, for whom there is a chance the fetus may develop methadone dependence. 
Methadone pharmacotherapy works best in combination with behavioral therapy (Alinejad 
et al., 2016). 
1.8.2.2. Buprenorphine. Buprenorphine is a narcotic drug derived from thebaine, 
used as a potential analgesic in many countries. Buprenorphine acts as a partial agonist at 
MOR and is approximately 30 times more potent than morphine, highly lipid soluble, well-
absorbed sublingually, but it has low bioavailability (Center for Substance Abuse 
Treatment, 2004). For the treatment of opioid addiction, buprenorphine can be used in two 
ways: long-term maintenance or detoxification from opioids. Its partial MOR agonist 
properties reinforce patient compliance with regular administration (Barnett et al., 2001). 
The most important characteristics of buprenorphine is that it does not produce euphoria 
and it can significantly decrease opioid withdrawal effects. That is why primary care 
physicians can safely prescribe buprenorphine for the case of opioid withdrawal (Kahan et 
al., 2011). 
1.8.2.3. Naltrexone. Naltrexone is a long-acting opioid antagonist which does not 
produce euphoria or addiction (Potenza, 2006). It is successfully used to reverse accidental 
heroin overdoses and treats opioid dependence. The main characteristics of the naltrexone 
is it can prevent a relapse to opioid use after heroin detoxification (Minozzi et al., 2011). 
For some patients, the main treatment goal is detoxification; methadone or buprenorphine 
detoxify slowly, but naltrexone has a faster detoxification capacity. Clonidine, an alpha 2 
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adrenergic agonist, is often used as a combination therapy with naltrexone for rapid opioid 
detoxification (Gowing et al., 2000). This treatment option seems extremely efficient, but 
different studies disagree about the claimed efficacy for opioid addiction treatment 
(Minozzi et al., 2011). 
1.9. Economic Effects of Opioid Addiction 
The economic consequences of opioid misuse and opioid use disorder has significantly 
impacted healthcare costs and public health. An analysis of an administrative database of 
a pharmacy claims shows that opioid abusers’ annual healthcare costs are 8 times higher, 
and drug costs are 5 times higher, than nonabusers. (White et al., 2005) In 2007, a total of 
$55.7 billion costs was associated with prescription opioid abuse, including $25 billion in 
healthcare costs, $25.6 billion in workplace costs, and $5.1 billion in criminal justice costs. 
Approximately $23.7 billion of healthcare costs are due to medical and prescription 
expenses. (Birnbaum et al., 2011) In 2013 the situation was even worse: the estimated costs 
rose to $78.5 billion, $22 billion more than in 2007. (Florence et al., 2016) Patients 
repeatedly receiving opioid therapy for severe pain have an increased morbidity. 
(Ballantyne, 2007) Healthcare cost can be lowered if opioid allocates and used properly. 
Mismanagement and misconceptions are the key to increase costs. Proper allocation and 
reduction of improper use of opioid can be lowered the health care costs. (Lipman & 
Webster, 2015) 
1.10. Methods for Determination of Analgesic Activity 
There are various methods to evaluate the analgesic activity of different drugs. These 
methods follow the general strategy that analgesic drugs can alter the effects of painful 
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stimuli (Davies et al., 1946). To screen for analgesic agents, nociceptive stimuli are 
administrated to the animals prior to administration of an analgesic. These painful stimuli 
produce animal responses indicative of painful sensations, including jumps, withdrawing, 
or licking or shaking of the paws, tail flick, skin twitch, or flight (Pircio et al., 1975). 
Popular methods for determining analgesic activity are explained below: 
1.10.1. Writhing test. Analgesic activity or anti-nociceptive activity of synthesized 
compound can be evaluated by a chemical method called the writhing test. In this method, 
different irritant compounds, like phenylquinone or acetic acid, are injected into the 
abdominal regions of mice or rats, inducing painful feelings, and increasing the frequency 
of writhing. After injecting an analgesic compound, the frequency of abdominal writhing 
should decrease significantly (Cruz, 1996; Gawade, 2012; Achar et al., 2010). This test is 
appropriate for testing the analgesic profile of the peripherally acting drugs, like 
chlorpromazine, antihistamine and meprobamate. But in this test, evaluation of analgesic 
duration is difficult, because the frequency of writhing decreases over time (Franklin & 
Abbott, 1989; Siegmund, 1957). 
1.10.2. Hot plate test. The hot plate test is another way to evaluate acute, 
cutaneous, thermal pain sensitivity. This test believed to evaluate a supraspinally organized 
nociceptive response because of the involvement of higher brain functions (Eddy & 
Leimbach, 1953). In this principle, rodents are placed onto a hot surface for a specific time 
frame and observed for nocifensive activity, like paw licking or jumping. Administration 
of an analgesic compound can increase the latency time to licking or jumping (Woolfe & 
MacDonald, 1944; O’Callaghan & Holzman, 1975). The hot plate test is relatively 
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complicated compared to other thermal assays because rodents show complex and subtle 
behavioral activities (Espejo & Mir, 1993) 
1.10.3. Von Frey tests. Von Frey tests are the set of tests to detect the noxious 
stimulus of a rodent due to stimulation of nociceptors. In this test, 50mm long a number of 
varying diameters Von Frey hair or fibers has been used. (Carter et al., 2010) Animal stands on 
an elevated mesh platform and von Frey hair inserted through the mesh to poke the animal’s 
hind paw. Normal reaction for the animal including withdrawing or licking or shaking the 
paws.  If animals show any of these kinds of reaction considered as a positive response. 
The exact force of the fiber is determined by its thickness. (Deuis et al., 2017; Minett et al., 
2014) 
1.10.4. Tail flick test. The tail flick test is one of the most common tests 
antinociceptive assays. Based on exposing rodents to a phasic thermal stimulus of high 
intensity and measuring the latency of the avoidance response (D'Amour & Smith, 1941). 
This model can be used for measuring acute nociception and it is not an injury model. 
(Irwin et al., 1951) In this method, radiant heat is applied to the tail of the animals, and the 
nociceptive sensitivity is determined by the tail–flick latency (D'Amour, Smith, 1941; Hole 
& Tjølsen, 1993). If this latency is prolonged by administering any drug or drug 
combination, that indicates analgesic activities of the test drug. But in this model, spinal 
transection above the lumbar level fails to block the tail–flick response, therefore it may 





1.10.5. Formalin test. The tail formalin test is a popular test to evaluate inflammatory 
pain due to injury. This model is useful to measure clinical pain because it affects 
inflammatory, neurogenic, and central mechanisms of nociception (Hunskaar and Hole, 
1987; Tjølsen and Hole, 1997). In this model, a dilute solution of formalin is injected onto 
the planter surface of a rodent’s hindpaw. Observation of the rodent’s stereotypical 
behaviors, such as flinching, licking, and biting of the affected hindpaw, are the 
measurements of inflammatory pain. These effects last 15-60 minutes (Lariviere et al., 
2002). This model is preferred over other models because both acute and tonic pain can be 
measured (Ibironke & Odewole, 2012). 
1.11. Need for New Analgesia & Strategy 
Opioids and NSAIDs have been used to treat pain for a long time. More effectiveness and 
less adverse effects are the considerable factors to develop new analgesic drugs. Since the 
choice of opioids are limited, so it is necessary to develop a new analgesic drug without or 
low abuse liability and side effects. In the middle of nineteenth century, morphine, a weak 
base, or alkaloid started use for minor surgical procedures, postoperative and chronic pain. 
(Brownstein, 1993) In 1939, meperidine discovered serendipitously which got the different 
structure than morphine. (Eisleb & Schaumann, 1939) In 1946, another compound like 
morphine synthesized called methadone. (Scott & Chen, 1946) After more than 100 years, 
morphine’s structure established, and total synthesis done in the laboratory. Bentley, 1987; 
Gates & Tschudi, 1956) In current studies, after analyzing structure activity relationship in 
4,5a-epoxymorphinan skeleton (Figure 1) some modifications in the structure of morphine 





Figure 1. 4,5α-Epoxymorphinan Template and Morphine. 4,5α-epoxymorphinan template 
(left) and morphine (right). The SARs of morphinan compounds have been primarily 







Discriminative Stimulus Effects of a Novel Atypical mu Opioid Receptor Agonist, 3-
Iodobenzoylnaltrexamide (IBNtxA) 
2.1. Introduction 
In order to identify novel opioids with better analgesic activity, limited or no side 
effects and no abuse potential, a group of scientists from Memorial Sloan-Kettering Cancer 
Center, New York, synthesized radiolabeled opioid derivatives. During this research, they 
characterized an atypical novel opioid, 3-Iodobenzoylnaltrexamide (IBNtxA), synthesized 
as a 6β-naltrexamine derivative of naltrexone (Figure #) with the following substitutions: 
methylcyclopropane at the R1 positions, hydrogen at the R2 position, and 3-iodobenzene at 
the R3 position (Majumdar et al., 2012). 
Further explorations into the pharmacological and chemical properties of IBNtxA 
found that IBNtxA is more potent than morphine animal models of analgesia. (Majumdar 
et al., 2011) and the tail flick model of analgesia (Grinnell et al., 2014). Other investigations 
found that IBNtxA had fewer side-effects compared to morphine. In mice, IBNtxA did not 
produce respiratory depression after administration of up to a 5-fold greater dose than its 
analgesic ED50. After chronical administration, it did not produce any physical dependence 
and cross-tolerance to the morphine. (Grinnell et al., 2014) IBNtxA also produced less 
slowing of intestinal transit, and no place preference when they tested single dose 






















Figure 2. SARs of  4,5-Epoxymorphinan Skeleton. SARs of  4,5-epoxymorphinan skeleton 
wherein the replacement of R1 at N-17 position by methyl cyclopropane, R2 at C-3 position by 
hydrogen and double bond with oxygen at C-6 position, produces opioid antagonist, naltrexone. 
Change in 4,5-epoxymorphinan skeleton at R1 and R2 same as naltrexone but replacement of R3 
by 3-idobenzene creates an atypical mu opioid receptor agonist IBNtxA which is a derivative 
of 6β-naltrexamine with higher analgesic effects but limited side effects than morphine and 
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A variety of genetic studies indicated that IBNtxA probably signals through 
truncated MOR splice variants—particularly exon 11-associated 6 transmembrane region 
splice variants (6TM/E11) (Majumdar et al., 2011). The loss of exon 11-associated MOR 
splice variants in knock-out (KO) mice caused a loss of IBNtxA-induced analgesia, but the 
analgesic effect of morphine was unchanged. When exon 1-associated MOR splice variants 
as well as DOR and KOR were knocked out, morphine analgesia was lost, but IBNtxA 
induced analgesia. These results indicate that IBNtxA may signal through 6TM/E11 
(Majumdar et al., 2011). A later study evaluated molecular models of full-length and 
6TM/E11 MORs in response to morphine and IBNtxA. Using homology modeling, 
docking and molecular dynamics, this study confirmed that morphine is unable to activate 
6TM/E11 MORs whereas IBNtxA can activate 6TM/E11 MORs, and with higher affinity 
over the full-length MOR (Sader et al., 2018).   
The characteristics and in vivo activities of 6TM/E11 are not well-established, 
though it’s been hypothesized that it can affect the analgesic signaling of other MOR 
agonists, such as morphine, buprenorphine, and methadone. (Grinnell et al., 2014, Lu et 
al., 2015; Majumdar et al., 2011). Based on these studies, IBNtxA appears to be one of the 
first compounds that might be preferential for 6TM/E11 receptors and could serve as the 
starting point for developing new 6TM/E11-selective compounds. 
In order to better understand the physiological effects of IBNtxA and probe whether 
it might be useful for evaluating 6TM/E11 signaling in vivo, it’s necessary to expand our 
understanding of IBNtxA pharmacology. Drug discrimination is a useful paradigm for the 
assessment of psychoactive properties of drugs to evaluate the safety profile, 
pharmacology, and possible drug abuse and drug dependency. It has been used to test novel 
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compounds compared to the standard established drugs, including therapeutic psychoactive 
drugs, like antidepressants, anxiolytics, antipsychotics, opioids, cannabinoids, and other 
compounds (Swedberg & Giarola, 2015; Porter et al., 2018). 
Drug discrimination testing can be performed using a wide variety of species, 
including mice, rats, pigeons, non-human primates, and humans. (Porter et al., 2018) Drug 
discrimination studies are useful for testing drug abuse liability and identification of 
underlying pharmacological actions and mechanisms of novel compounds because a test 
compound that substitutes for a training drug is understood to share the discriminative 
stimulus and pharmacological properties of that training drug. (Colpaert, 1999) This 
procedure requires extensive training of animals to learn to identify the effects of an 
administrated training drug or a vehicle control (Porter et al., 2018). Once fully trained, 
test drugs can be administered and the behavioral response of the animal will be driven by 
the test drug’s discriminative stimulus effects (Catania, 1971).  
In this study, we investigated the discriminative stimulus effects of IBNtxA (3′-
iodobenzoyl-6β-naltrexamide) compared to other opioid receptor ligands to better 
understand the subjective effects of IBNtxA and more thoroughly evaluate its abuse 
liability. 
2.2.  Materials and Methods 
This experiment used drug-naïve adult male C57BL/6 mice obtained from Charles 
River Laboratories (Wilmington, MA). The animals were housed in the temperature- and 
humidity-controlled vivarium located in Cooper Medical School of Rowan University. 
This vivarium has a barrier facility and animals kept under a 12 h light/dark cycle (lights 
on at 0700, off at 1900). Animals were group housed (four animals/cage) in polycarbonate 
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cages with ad libitum food and water and enrichment provided by paper Bio-Huts and/or 
nestlets. Mice arrived at the facility approximately 28 days of age and were equilibrated to 
the facility for a minimum of seven days before beginning testing. One group (7 animals) 
of mice were used for the drug discrimination studies. Though mice have adequate access 
to water and air, but they were food restricted for 6-12 hours prior to experiments. Animals 
were trained with IBNtxA 3mg/kg and DMSO vehicle (10% DMSO and 90% saline). After 
couple of months training, well-trained animals were tested with different doses of novel 
drug IBNtxA, µ opioid receptor agonist (Morphine), partial agonist at µ and nociceptin 
opioid receptor and antagonist at δ and κ receptors (Buprenorphine), κ opioid agonist 
without µ opioid antagonist effects (U-50488), potent and selective non-peptide δ opioid 
receptor agonist (SNC 162) and Selective and potent nociceptin opioid receptor agonist 
(SCH 221510) 
2.3. Animals 
The C57BL/6 strain of mice is a typical inbred strain, most widely genetically modified 
laboratory mice for biomedical, pharmaceutical, translational science or any animal study 
research (Figure 3). These animals are widely used in different studies because of their 
availability and robustness. This strain of animal was first developed by C.C. Little in 1921 
which was eventually handed over to Charles River in 1974 from NIH. (Chia et al., 2005; 
River, 2018; Sarna et al., 2000) They are deep brown or almost black (Figure) in color. 
Their important characteristics is, they are highly sensitive to noise and odors; not docile 
like CD-1 mice and more likely to bite. They are barbering in nature, and dominant mice 
can remove hair and whisker of housemates. (Sarna et al., 2000, Willott et al., 1995) These 
animals are highly susceptible to addiction, atherosclerosis and age-related hearing loss. 
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(Willott et al., 1995) Like CD-1 mice, this strain also grows with time, reaching full weight 
after fifteen weeks; we started to weigh them after five weeks, and the average approximate 












IBNtxA was synthesized at Rowan University by using a multi-step laboratory 
synthesis. Initially commercial naltrexone (Tocris) was converted into naltrexamine. This 
naltrexamine reacted with 2,5-dioxopyrrolidin-1-yl-3-iodobenzoate and purified to 
produce the IBNtxA used for this experiment. This synthesis was performed in the 
laboratory of Dr. Gustavo Moura-Letts. 
Morphine sulfate was purchased from Henry Schein (Melville, NY). Cocaine HCl was 
purchased from Sigma Aldrich (St. Louis, MO). Buprenorphine, naltrexone, U-50488, 
Figure 3. C57 Mouse. Image of deep brown or black colored C57BL/6 
genetically designed animal. These mice are odors sensitive; are highly 
susceptible to addiction, atherosclerosis, and age-related hearing loss. They are 
barbering in nature, prone to engage fighting with inmates, resulting hair 
removal and sometimes possible injuries. (River, 2018; Sarna et al., 2000; 
Zurita et al., 2011) 
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SCH 221510, and SNC 162 were purchased from Tocris (Minneapolis, MN). All drugs 
were administered via intraperitoneal (i.p.) injection at a volume of 10 mL/kg to the 
animals. Since body weight is an important factor to measure the dose of drug, dilutions 
were premixed to provide a given mg/kg dose prior to every test. For example, a 20 g 
mouse would receive a 1 mg/kg drug dose via the injection of a 0.20 mL volume of a 0.1 
mg/mL drug solution. IBNtxA was delivered in a 10% DMSO vehicle, prepared via 
stepwise mixing with 10% dimethyl sulfoxide (DMSO) and 90% physiological saline. All 
other drugs were readily dissolved in the same 10% DMSO vehicle. All drugs were kept 
secure inside a locker with a regulated inventory procedure under the control of Dr. 
Bradford Fischer, who holds controlled substances licenses from the State of New Jersey 
and the U.S. Drug Enforcement Agency. 
2.5. Apparatus 
For drug discrimination training and testing, mouse operant chambers (Med Associates, 
Fairfax, VT) were used. (Figure 4) Each apparatus was positioned in sound-attenuating 
cabinets and connected to a computer running MED-PC software (version 4). The drug 
discrimination apparatus was a small box made of transparent acrylic and containing two 
nose poke holes. One hole was designated as the “drug side” and the other was designated 
as the “vehicle side” (Figure 5). A liquid dipper was located between those two nose poke 
holes, connected via tubing to a pump and syringe that discharged vanilla Ensure for 3 
seconds (delivering an approximate 0.1 mL volume) as a palatable food reward. The nose 
poke holes were equipped with infrared beams; when animals nose poked on either side, 





















Figure 4. Drug Discrimination Testing Apparatus. Image of drug 
discrimination testing apparatus from our research lab. There are two nose 
poke holes and mice can easily poke those holes for finding rewards. The 
activity of animals is tracked by infrared and then signal is sent to MED-PC 
software to analyze and present on the monitor. The left hole is vehicle-paired; 
if animals knock this hole on vehicle-training session is considered as correct 
response and the right hole is drug-paired; on drug-training session if animals 
knock this hole, is considered as correct response. For every five correct nose 
pokes, animals receive one single reward which is three seconds Ensure Plus 
syrup discharge through reward spout. During substitution test day any nose 
pokes to either side are considered for reward. The speaker on top of image is 




Before training/testing, animals were food restricted up to 18-20h.  Though animals do 
not have any available food, but they have ad lib access to water. The overall training 
procedure is represented in the overall procedure is represented by Figure. During training, 
each animal was injected with either 3 mg/kg IBNtxA or vehicle control. To earn the food 
reward, animals were required to complete a specific set of correct responses: the required 
number of correct responses to achieve a reward is known as the fixed ratio (FR). Training 
initially started with an FR1 and increase up to FR5 based on their training improvement. 
I took almost 2 months to reach FR5. An FR5 training paradigm, animals required to 
complete 5 correct nose pokes in a row to earn a reward. MED-PC software controlled the 
entire system. All rewards were accompanied by light and tone stimuli during the duration 
of the 3-second reward delivery. 
Mice were trained initially to nose poke for Ensure rewards using a fixed-ratio 1 (FR1) 
schedule, in which a single nose poke on either side initiated reward delivery and associated 
cues. Following successful nose poke training, in which mice received at least 90 of 100 
possible rewards in a 1-hour time period, animals were trained to discriminate between 
DMSO vehicle (10% DMSO and 90% saline) and 3 mg/kg IBNtxA. During the training 
phase, mice received i.p. injections of 3 mg/kg IBNtxA or DMSO vehicle and were placed 
in the operant chamber 15 minutes prior to the start of training, with the start of the session 
indicated by a house light turning on. IBNtxA and vehicle were given with a pseudorandom 
order of training to avoid day-of-the-week training effects. For all chambers, IBNtxA was 
programmed to be associated with the right nose poke hole, and DMSO vehicle with the 
left nose poke hole. In order to earn an Ensure reward, animals were required to complete 
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an unbroken FR response in the correct nose poke hole. Over the course of training, the FR 
requirement was increased until mice were correctly nose poking >90% on a FR5 schedule; 
mice were considered to have successfully learned the DD procedure at a given FR level 
when ≥ 90% of the initial 10 nose pokes in a given training session matched the desired 
response. All training sessions lasted for 60 minutes or until 100 rewards were earned. 
Before and after all training and testing procedures, each test apparatus and floor insert 
were cleaned with 70% isopropyl alcohol and allowed to dry completely. 
After meeting FR5 training criteria, mice were tested with varying doses of IBNtxA 
(0.33-3.0 mg/kg), morphine (0.33-10 mg/kg), U-50488 (0.33-10 mg/kg), buprenorphine 
(0.10-1.0 mg/kg), SNC162 (3-18 mg/kg), SCH 221510 (1-10 mg/kg) and cocaine (3-10 
mg/kg) given via i.p. injection. For each test, mice were given a drug injection and placed 
in the operant chamber 15 minutes prior to the start of testing session, with the start of the 
session indicated by a house light turning on. Drug discrimination was measured by the 
first response (drug side or vehicle side) after the start of the session, after which the session 
was immediately ended with no rewards given. This limited, stringent testing procedure 
was adopted after initial studies determined that IBNtxA discrimination training was easily 
disrupted by rewards earned while exposed to some tested drugs (possibly owing to 
IBNtxA being a relatively weak discriminative stimulus). This procedure allowed much 
quicker (~1 week) re-establishment of drug discrimination between tests, but it also results 
in data that are less typical of DD reports in the literature: instead of reporting the 
proportion of overall nose pokes (drug-paired vs. vehicle-paired) following testing, we 
report the proportion of animals whose initial responses were on the drug-paired vs. 
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vehicle-paired side. Likewise, because we cannot report standard drug effects on response 



























Correct responses (5) 
Reward (3 seconds disposal) 
Reward continuing 
Reward End (After getting 
100 rewards or 60 Minutes 
After 15 minutes 
Figure 5. Outline of drug discrimination training. From the top of this image, 
after receiving an injection (i.p.), animals are placed inside operant chamber. 
The trial starts 15 minutes later. Each subject receives a reward of three 
seconds liquid food dispensed via a reward spout for every five correct 
responses. The training sessions automatically end after either earning 100 




A group of animals contained Seven C57BL/6 mice has been trained. The animals 
were trained with vehicle (10% DMSO and 90% Saline) and IBNtxA 3 mg/kg. To train 
mice properly and unbiasedly, the pattern of training was always being changed in each 
day for overcoming any possible effect of training schedule pattern which might affect 
discrimination study. 
The animals that could not reach the standard training with minimal 80% initial correct, 
80% total correct response and 80% reward were excluded beforehand. Furthermore, every 
animal was kept in close observation for any health issue such as weight loss, stool 
condition, any possible injuries etc. Sick animals were separated from other mates and 
treated with required medicines. The animals with better health were trained and tested 
only.   
2.7. Statistical Analysis 
  Following equations were used for analysis: 
For training. 
% of total correct responses = (
Total correct responses
Total correct responses + Total incorrect responses
) × 100 
 
% of initial correct responses = (
Initial correct responses 
Initial correct responses + Initial incorrect responses
) × 100  
 
2.8. Time to First Response 
Drug discrimination was measured by the first response (drug side or vehicle side) after 
15 minutes of the session started. This is important to study drug discrimination, because 
how the animals feel like after the administration of a drug. An immediate response 
confirmed the appropriate training dose and the possible range of dose which might be 
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tested for a drug  This limited, stringent testing procedure was adopted after initial studies 
determined that IBNtxA discrimination training was easily disrupted by rewards earned 




Seven mice were trained to discriminate 3 mg/kg IBNtxA from 10% DMSO vehicle. 
IBNtxA proved to be a weak discriminative stimulus and training took approximately 90 
days in order for all animals to meet training criteria (> 80% correct responses). Initial 
experiments revealed that drug trials in which animals could respond for 30 minutes 
substantially disrupted subsequent discrimination training and required extended re-
training between drug tests. Therefore, drug tests were redesigned to count only the initial 
(unrewarded) nose poke after test drug delivery 15 minutes prior to the start of the trial. 
Only results from this second iteration are presented in Figure 3; panel A indicates the first 
nose poke response for each tested drug dose and panel B indicates the time to initial nose 
poke response, an indication of whether a drug dose was behaviorally disruptive. 
Initial test trials with DMSO vehicle and 3 mg/kg IBNtxA (black squares) indicated 
that this method could reliably distinguish vehicle from training drug. Dose responses were 
then recorded for IBNtxA (0.3-3 mg/kg), MOR agonist morphine (0.33-10 mg/kg), KOR 
agonist U-50488 (0.33-10 mg/kg), DOR agonist SNC162 (3-18 mg/kg), NOP agonist SCH 
221510 (1-10 mg/kg), and MOR partial agonist/NOP agonist buprenorphine (0.10-1 




Figure 6. Drug Discrimination Results. Drug discrimination results for animals 
trained to distinguish 3 mg/kg IBNtxA from vehicle. A. IBNtxA and KOR agonist 
U-50488 fully substitute for IBNtxA. MOR agonist morphine, DOR agonist 
SNC162, NOP agonist SCH 221510, MOR partial agonist/NOP agonist 
buprenorphine partially substitute for IBNtxA. The psychostimulant cocaine does 
not substitute for IBNtxA. Because these data ultimately represent the proportion of 
mice who chose the IBNtxA-paired nose poke hole for their first response, there are 
no error bars. B. Behavioral disruption of drug responding as determined by the time 
to first drug response. The highest tested doses of buprenorphine, morphine, SCH 
221510, and cocaine each induced a substantial behavioral disruption. These results 




IBNtxA dose-dependently and fully substituted for itself. MOR agonist morphine, 
DOR agonist SNC162, NOP agonist SCH 221510 and MOR partial agonist/NOP agonist 
buprenorphine each partially substituted for IBNtxA, while the psychostimulant cocaine 
did not substitute for IBNtxA (Figure 7A). At the highest doses tested, morphine (10 
mg/kg), SCH 221510 (10 mg/kg), and buprenorphine (1 mg/kg) each disrupted responding 
(Figure 7B). KOR agonist U-50488 fully substituted for IBNtxA, indicating that KOR 
signaling effects are likely crucial to the in vivo characteristics of IBNtxA. First drug 
response time is important because behavioral disruption of drug response is determined 
by using the first drug response time. The highest doses of morphine (10 mg/kg), SCH 
221510 (10 mg/kg), cocaine (10 mg/kg), and buprenorphine (1 mg/kg) showed the 
disrupted response and for 10 mg/kg morphine and 1 mg/kg buprenorphine, drug 
substitution data couldn’t be presented. The reason for this because of the animals’ failure 
of nose poke on either the drug or vehicle side. That is why drug substitution data are not 
available for 10 mg/kg morphine and 1 mg/kg buprenorphine. 
2.10. Discussion 
IBNtxA have a crucial analgesic effect to alleviate moderate to severe pain. During 
cancer or major surgery, patient needs more potent analgesics. The effects of IBNtxA is 
compared to the effects of IBNtxA. KOR agonist U-50488 fully substituted for IBNtxA, 
indicating that KOR signaling effects are likely crucial to the in vivo characteristics of 
IBNtxA. Since, IBNtxA partially substituted by DOR, MOR, and NOP agonists, and fully 
substituted by a KOR agonist in the drug discrimination assays indicate that these receptors 
may each contribute to IBNtxA-mediated analgesia. This is the first time to test the 
discriminative stimulus properties of IBNtxA. Though the discriminative stimulus 
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properties of 6TM/E11 agonism are not established yet. But it is known that opioid agonists 
have important effects mediated by 6TM/E11 activation (Majumdar et al. 2011b; Marrone 
et al. 2016). There are some limitations of this study. In this test, all tests performed by 
using male mice, not female mice. There are some sex-mediated differences in opioid 
receptor expression and signaling, manifesting in differential effects in tests of analgesia 
in humans and rodents and important differences in rodent models of drug abuse and 
relapse (Becker & Chartoff, 2019; Craft, 2008; Dahan et al., 2008; Lee & Ho, 2013). 
IBNtxA showed full KOR agonism in male mice but sex difference may impact in 
analgesia and abuse liability. (Chartoff & Mavrikaki, 2015) The animals housed in 
light/dark cycle, but experiment performed only in the light part. So, the inactive part of 
the mouse diurnal cycle may provide variable opioid receptor expression. (Mitchell et al. 
1998) and opioid receptor activation can itself alter circadian rhythms (Pacesova et al. 
2015; Webb et al. 2015).  If the tests performed in dark cycle, there is a possibility to get 













Synergistic Analgesic Effects of Morphine and the Novel α2/3-Preferring GABAA 
Receptor Positive Allosteric Modulator MP-III-024 
3.1. Introduction 
Pain is a complex phenomenon involving numerous neurotransmitters and their end 
target receptors. The currently available analgesics to treat pain include opioids, however 
this class of drugs also carries dose-limiting adverse effects and the potential risk vs benefit 
must be considered when prescribing (Mao, 2015). Opioid receptors are distributed both 
within and outside the central nervous system (CNS), and mediate effects producing both 
therapeutic properties such as pain relief and a broad spectrum of adverse effects including 
sedation, respiratory depression and constipation, as well as tolerance and physical 
dependence following chronic use. 
3.1.1. GABA. γ-aminobutyric acid (GABA) works as a chemical messenger in the 
CNS where it functions as an inhibitory neurotransmitter. Among the two major classes of 
GABA receptors, ionotropic GABA type A (GABAA). This GABAA receptors are in the 
ligand gated ion channels family. (Ferando & Mody, 2014) GABAA receptors include αβγ2 
isoforms on which benzodiazepine-type drugs function as positive allosteric modulators 
(Fritschy, 1997). These receptors incorporated in postsynaptic membrane and mediate 
transient and fast synaptic inhibition within milliseconds.  GABAA receptors also located 
at the extrasynaptic places mostly surrounded by GABA and occurs long term inhibition. 
(Rudolph & Knoflach, 2011) These GABAA receptors are differentially distributed within 
the CNS, and receptors containing α2 and α3 subunits next to the γ2 subunit (α2-containing 
GABAA and α3-containing GABAA receptors, respectively) are expressed in dorsal horn 
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spinal pathways and have been implicated in nociceptive transmission. Previous work has 
demonstrated antihyperalgesic effects of intrathecally administered benzodiazepines 
(Knabl et al., 2008, 2009; Witschi et al., 2011) as well as systemically delivered compounds 
with functional selectivity for α2GABAA and α3GABAA receptors (Knabl et al., 2008; Di 
Lio et al., 2011, Paul et al., 2013; de Lucas et al., 2015, Fischer et al., 2017). 
The expression of both opioid, α2GABAA and α3GABAA receptors in nociceptive 
pain pathways raises the possibility of interactive effects of concurrent administration of 
compounds that modulate each receptor. If greater than additive effects are detected on 
endpoints related to pain reduction, combination therapy may be useful to tread pain-
related disorders. Recently a novel benzodiazepine-type compound methyl 8-ethynyl-6-
(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate (MP-III-024) was 
described (Fischer et al., 2017). MP-III-024 displayed preference for α2GABAA and 
α3GABAA receptors and produced antihyperalgesic effects with limited off-target effects 
as measured with operant responding and locomotor activity. MP-III-024 also 
demonstrated a similar time course and duration of action relative to morphine making it 
ideal for combination studies. 
The use of dose-addition analysis is one method used to provide a quantitative 
evaluation of drug interactions and can be used to differentiate effects that are additive 
from effects that are subadditive or supra-additive (synergistic) (Fischer, 2011). In the 
present study, dose-addition analysis was used to evaluate α2GABAA receptor/α3GABAA 
receptor-opioid interactions. The effects of combinations of MP-III-024 and the 
prototypical mu opioid agonist morphine were examined in CD1 mice using two different 
assays. To assess the extent to which interactive effects occur on an endpoint related to 
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inflammatory pain, the zymosan A model of mechanical hyperalgesia was used. Second, 
the acute thermal antinociceptive effects of MP-III-024, morphine and their combinations 
were evaluated in the hot plate procedure. Drug interactions were assessed using a fixed-
proportion design, since this has been recommended for the study of drug interactions 
(Fischer 2011) and has been used to study similar drug mixtures on similar endpoints 
3.2. Materials and Methods 
All experiments used adult male CD-1 mice 10 weeks of age obtained from Charles 
River Laboratories (www.criver.com). Animals were housed in the temperature- and 
humidity-controlled vivarium with constant access to air and water, under a 12h light/dark 
cycle (lights on at 7:00 AM). Mice were grouped in polycarbonate cages with ad libitum 
food and water and enrichment provided by paper Bio-Huts and/or nestlets. Mice were 
habituated to the colony room environment for 2 weeks prior to any experimental 
manipulation and exposed to the testing environment and handled for 2 days prior to 
initiation of an experiment. All testing procedures were conducted between 11:00 AM and 
3:00 PM. Animals used in this study were cared for in accordance with the guidelines of 
the Institutional Animal Care and Use Committee of Rowan University and all testing 
adhered to the “Guide for the Care and Use of Laboratory Animals” (National Research 
Council, National Academy of Sciences, Washington, D.C., USA, 2011). 
3.3. Animals 
CD-1 laboratory mice are widely used in biomedical and pharmaceutical research. 
(Figure 8) Most of the currently used mice are the progeny of nine Swiss mice, two male 
and seven female albino mice, which were imported to the USA in 1926 by Dr. Clara Lynch 
of the Rockefeller Institute for Medical Research, now named Rockefeller University (Chia 
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et al, 2005). In 1948, new Ha/ICR mice were initiated from previously imported 
Rockefeller “Swiss” mice at the Institute for Cancer Research (ICR) in Philadelphia. (Chia 
et al., 2005)  
We started experiments when animals were around 35 days old, at which the 
average weight of mice was approximately 22-25 g. When we were working with CD-1 
mice, in our observation, they were usually easy to handle but were quite variable in their 
activity during the first week, especially during drug administration. The reason behind 
their aggressive behavior during the first few days was likely the time need for adaptation 















Figure 7. CD-1 Outbred Mouse. Image of white colored CD-1 outbred 
mouse. These mice are docile in behavior and widely used in biomedical 
research. They are normal wild type mice, grow over time and gains 




The novel benzodiazepine analog methyl 8-ethynyl-6-(pyridin-2-yl)-4H-
benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate (MP-III-024) was synthesized at the 
Department of Chemistry and Biochemistry at the University of Wisconsin-Milwaukee. 
Morphine was purchased from Sigma-Aldrich (St. Louis, MO). Drugs were suspended in 
0.5% methyl cellulose and 0.9% NaCl and administered intraperitoneally in a total volume 
of 10 ml/kg body weight. 
3.5. Hot Plate Testing 
3.5.1. Background. Antinociception during the hot-plate procedure was assessed 
using a hot plate analgesia meter (25.3 × 25.3 cm; Columbus Instruments, Columbus, OH, 
USA) maintained at 56 ± 0.1°C. The antinociceptive response was evaluated by recording 
the latency to lick or shuffle the hind paw(s) and/or to jump from the hot plate surface. A 
predetermined cutoff time of 20 s was defined as a maximal response and was employed 
to prevent tissue damage. The antinociceptive response was measured twice at 30 and 15 
min prior to the beginning of drug administration and these data were averaged to yield 
one baseline value.  
3.5.2. Apparatus. The hot plate analgesia meter (Columbus Instruments, OH, 
USA) for small laboratory animals were used for this analgesic test. (Figure 9) The hot 
plate could continuously provide 55 °C temperature on an aluminum surface, with a digital 
built-in thermometer to maintain surface temperature to 0.1 °C precision and a timer with 
a 0.1 sec precision. The square shaped surface plate was enclosed by a clear acrylic cage 
to confine animals during testing. Pushes on start/stop button related to the timer, which 












3.5.3. Procedure. The hot plate was set at 56 °C to observe the effects of drugs on 
animals. Certain behavioral changes, paw licking, flutter, and jumping, were considered as 
an animal’s pain feeling. (Rezaee-Asl, Sabour, Nikoui, Ostadhadi, & Bakhtiarian, 2014) 
Latency time after placing mice on the metallic hot plate provided the threshold level of 
animals. Prior to injecting the drug, each mouse was weighed and tested for two baseline 
studies where the animal was not injected with any drug or vehicle. After baseline studies, 
testing drug was administrated and animals were placed on hot plate in 15, 30, 45, 60, 
and/or 75/90 minutes time intervals to collect the latency time. If any behavioral change 
like paw licking, flutter or jumping had been observed, the mouse was immediately 
removed from hot plate and latency time was recorded. Animals were removed from hot 
plate after 20 seconds even though there was no considerable behavioral change to avoid 
tissue damage and this specific time is known as maximum latency time. Any animal which 
Figure 8. Hot Plate Apparatus. Image of hot plate apparatus with a CD-1 
mouse from our research lab. The hot plate has an aluminum flat surface 




showed more latency time more than 20 seconds was excluded from further investigation. 
(Menéndez, Lastra, Hidalgo, & Baamonde, 2002; Rezaee-Asl et al., 2014) 
3.5.4. Statistical analysis. The anti-nociceptive effect for each dose was calculated 
as the % of the Maximal Possible Effect (% MPE) using the following formula: 
 % 𝑀𝑃𝐸 = (
Latency time after drug administartion−Mean latency time of baseline studies
{ Maximal latency time (20)−Mean latency time of baseline studies}
) × 100 
3.6. Von Frey Test 
3.6.1. Background. Antihyperalgesic effects were studied following inflammation 
evoked through subcutaneous injection of 0.06 mg zymosan A suspended in 20 µl 0.9% 
NaCl into the plantar surface of the right hindpaw. The non-injected left hindpaw was used 
as control. Mechanical sensitivity was then assessed 24 h after zymosan A injection by 
applying von Frey filaments of increasing stiffness (5-26 g) to the mid plantar surface of 
the hind paws until the filament bends (IITC Life Sciences, Woodland Hills, CA). A 
positive response evoked a paw withdrawal behavior and mechanical threshold was defined 
as the minimum force necessary to elicit a positive withdrawal response.  
3.6.2. Apparatus. The von Frey platform was set up above eye level and placed in 
a place the room in order to allow to move around all sides of the platform without impeded 
access. The Von Frey test is basically a mechanical sensitivity test which consists a set of 
thin calibrated plastic filament that are applied to the plantar surface of the hind paw while 
testing. Von Frey filaments of increasing stiffness (0.008-300 g) are used to determine the 
threshold that produces a hind paw withdrawal response. The mechanical withdrawal 




























Figure 10. Von Frey Filaments. Image of von Frey filaments from our 
research lab.  
Figure 9. Von Frey Set Up. Image of the von Frey setup from our research 
lab. The setup has a mesh surface where mice can move freely. 
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3.6.3. Procedure. Prior to injecting the drug, each mouse was weighed and tested 
for two baseline studies where the animal was not injected with any drug or vehicle. After 
baseline studies, testing drug was administrated and animals were placed on wide gauge, 
wire mesh surface in 15, 30, 45, 60, and/or 75/90 minutes time intervals and Von Frey 
filaments of increasing stiffness had been applied until the filament bends. If the mouse 
responds by flicking its paw away from the stimulus 3 times by the same size filament, the 
filament diameter size has been recorded. The process is repeated with increasing gauges 
















Figure 11. Von Frey Testing Procedure. Image of von Frey testing 
procedure from our research lab. Using von Frey hair, poking plantar 
surface of the animal’s footpad. 
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3.6.4. Statistical analysis. The mechanical threshold following drug administration 
was normalized to the baseline measurement of the non-injected left hind paw and 
expressed as a percentage of the maximal possible effect (%MPE) from the following 
formula:  
% 𝑀𝑃𝐸 = (
post drug right paw threshold (g) − baseline right paw threshold (g) 
baseline left paw threshold (g) − baseline right paw threshold (g)
) × 100 
3.7. Isobolographic and Dose-Addition Analysis 
Interactions between MP-III-024 and morphine were assessed using both graphical and 
statistical approaches (Wessinger, 1986; Tallarida, 2000). Using the graphical approach, 
the distinction between subadditive, additive, or synergistic interactions were made with 
the use of isobolograms. In the current study, isobolograms were constructed by connecting 
the ED50 of MP-III-024 alone plotted on the abscissa with the ED50 of the morphine alone 
plotted on the ordinate to obtain an additivity line. The additivity line contains the loci of 
dose pairs that produce an ED50 equal to the ED50 of MP-III-024 or morphine alone. Dose 
pairs that fall below the additivity line suggest an ED50 was reached with lesser quantities 
of the drugs, suggestive of synergism. In contrast, experimental points representing dose 
pairs that fall above the line are suggestive of subadditivity. 
Drug interaction can be analyzed in different ways. Among them, a comparison of 
the ED50 values for each mixture with the predicted additive ED50 values is a good way 
to determine the potency of the prospective combination drug. ED50 values for each 
mixture can be represented by Zmix and predicted additive ED50 values can be represented 
by Zadd. (Tallarida, 2011) Total drug dose of MP-III-024 and morphine which can produce 
a 50% maximum possible effect can be called Zmix. If two drugs Morphine and MP-III-
024 added together in a specific ratio, and if they did not do anything special, that is 
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predicted additive ED50 (Zadd). In this mechanical sensitivity assay, if both drugs were 
effective equally, an equation Zadd = fA + (1 - f)B can be used to calculate Zadd values 
individually. In that equation, A is the ED50 for MP-III-024 alone, B is the ED50 for the 
morphine alone, and f is the fraction. For determining the proportion of MP-III-024 in each 
mixture equation fA/[fA + (1 - f)B] can be used. This study examined effects produced by 
mixtures in which f = 0.25, 0.5, and 0.75. When f = 0.25, the mixture contains a proportion 
of [A/(A + 3B)] MP-III-024 and a mixture ratio of [(A/B)/3] parts MP-III-024 to one-part 
morphine; f = 0.50 leads to a proportion of [A/(A + B)] MP-III-024 in the mixture and a 
mixture ratio of (A/B) parts MP-III-024 to one-part morphine; and f = 0.75 leads to a 
proportion of [A/(A + B/3)] MP-III-024 in the mixture and a mixture ratio of [(A/B) × 3] 
parts MP-III-024 to one-part morphine. 
Isobolograms represents the analgesic effects in the hot plate assay (A) and the von 
Frey test (B) with morphine alone, or morphine in combination with MP-III-024. In 
combination study, after plotting the ED50 on isobologram, three either cases can be found. 
Points can be on additive line or lower-left side or upper-right side. If it is on the additive 
line, there are no significant effects of this combination. When it falls the lower left side, 
which represents a synergistic effect of the combination. On the other hand, falling on the 
upper-right side represents subadditive or counterproductive effects. Tested with the 
mixture in different ratios in both hot plate assay and the von Frey test, there is some 
leftward shift of the ED50 values on isobologram noticed. That’s why more potency of this 






Figure 12 shows the dose response curves for morphine and MP-III-024 
administered alone in both the hot plate and von Frey procedures. In the von Frey 
procedure, injection of zymosan A into the right hind paw reduced mechanical sensitivity 
relative to the non-injected left hind paw and paw withdrawal thresholds of the non-injected 
paw were unaffected (data not shown). In this assay (right panel) each compound produced 
dose- and time-dependent increases in mechanical sensitivity as expressed as %MPE. A 
statistical test for parallelism revealed that the morphine and MP-III-024 dose-effect curves 
were parallel (p < 0.05). These relative potency values were used to determine relative 
proportions of the compounds used in subsequent studies assessing MP-III-024/morphine 
mixtures. Figure 12 (left) also shows the antinociceptive effects of morphine and MP-III-
024. Morphine produced dose-dependent increases in latency to respond on the hotplate, 
and the resulting ED50 value of 12 mg/kg. MP-III-024 was without effect in this assay, 
therefore, the relative potencies determined in the von Frey procedure were used to 

























Figure 13 shows the antihyperalgesic effects of morphine alone and in combination 
with MP-III-024. Each drug mixture produced dose-dependent decreases in response rates. 
Addition of MP-III-024 produced concentration dependent leftward shifts in the morphine 
dose-effect curve. Figure 14 also shows the antinociceptive effects of morphine alone and 
in combination with MP-III-024. In this procedure, each drug mixture produced dose-
dependent increases in antinociception, and addition of MP-III-024 again produced 
leftward shifts in the morphine dose-effect curve.  
 
 
Figure 12. Dose-Effect Curves of Analgesic Effects (Single Drug). Dose-effect 
curves of analgesic effects in the hot plate assay (A) and the von Frey test (B). 
Morphine was a potent analgesic in both tests but MP-III-024 only produced 
analgesia in the von Frey test. On hot plate assay (A), MP-III-024 shows almost 
no analgesic effects with the 3.2mg/kg, 10mg/kg and 32mg/kg doses. 
Increasing doses of MP-III-024 does not show any significant effects. On the 
Von Frey assay (B), MP-III-024 and Morphine showed effectiveness 
simultaneously. Though not significantly, the effects of MP-III-024 is better 













The isobolographic graphical analysis of the drug combinations is shown in Fig. 
15. In the von Frey procedure (right), the 0.31:1 MP-III-024/morphine mixture produced 
additive effects as these ED50 values fell close to the line of additivity. Statistical 
comparison of experimentally determined ED50 values (Zmix) and predicted additive ED50 
values (Zadd) confirmed these findings (i.e., Zadd = Zmix) (insert values). In contrast, the 
0.94:1 and 2.8:1 MP-III-024/morphine mixtures produced supra-additive (synergistic) 
effects as these ED50 values fell below the line of additivity, and these observations were 
also confirmed with statistical dose-addition analysis. On the hot plate procedure (left 
panel). Graphical analysis of the MP-III-024/morphine mixtures indicates that each 
mixture produced supra-additive effects because these ED50 values fell to the left of the 
Figure 13. Dose-Effect Curves of Analgesic Effects (Drug combination). Dose-effect 
curves of analgesic effects in the hot plate assay (A) and the von Frey test (B) with 
morphine alone, or morphine in combination with MP-III-024. The addition of MP-
III-024 induced a leftward curve shift in each assay. The effect of any combination is 
better than the effect of Morphine alone in both the platforms. Though MP-III-024 is 
not effective on Hot Plate at all, it might increase the activity of Morphine. As a result, 
the maximum effectiveness achieved by the relatively low combination doses than 
Morphine alone. This synergistic effect indicates the effect of combination doses and 




line of additivity. Statistical comparison determined that the experimentally determined 
ED50 values (Zmix) for these mixtures were significantly less than the predicted additive 
ED50 values (Zadd). If the combination drug does not have any synergistic effects, the 
points of ED50 values should fall on the additive line. When it produces some extra effects 
for the combination, the points of ED50 values should fall on the lower left quadrant of the 
additive line and if this combination slows down its potency, it should fall on the upper 














Figure 14. Isobolographic analyses. Straight line indicates the additive effects of the 
combination. Lower-left shift means the synergistic or super additive properties of drug 
combination and upper-right shift represents the counterproductive or sub additive 



















In the von Frey procedure, each compound produced dose- and time-dependent 
increases in mechanical sensitivity, whereas only morphine was effective on the hot plate. 
In combination of 0.94:1 mixture of MP-III-094 and Morphine demonstrate the two drugs 
interact in a synergistic manner across both procedures. 
The measurement of variations in withdrawal responses is an important tool used to assess 
changes in tactile sensitivity in rodent models of pain and inflammation. Using a von Frey 
apparatus to assess these changes in tactile sensitivity. On Hot plate, at 56 °C temperature, 
nociceptive behaviors including paw licking, flutter, and jumping can be observed, and 
Figure 15. Isobolographic Analyses (Drug combination). Isobolographic analyses 
of analgesic effects in the hot plate assay (A) and the von Frey test (B) with 
morphine alone, or morphine in combination with MP-III-024. Because MP-III-
024 was ineffective in the hot plate assay, the line of additivity is vertical in panel 
A at the determined ED50 of morphine. All combinations of morphine with MP-
III-024 significantly induced synergistic effects. In the von Frey assay, the line of 
additivity spans from the determined ED50 values of morphine and MP-III-024; 
combinations of the two drugs fell into the lower left quadrant, indicating 
synergistic effects. Both the isobols show that E50 values are into the lower left 
quadrant which means for getting a similar effect with Morphine alone, lower dose 
is needed with the combination therapy. High doses of analgesics are responsible 




increased response latencies following drug administration are interpreted as an 
antinociceptive response. These two techniques show two different effects for the two 
different drugs. But in combination, synergistic effects suggest a new combination of 
analgesic by using low doses and obtain higher efficacy. There are some limitations of this 
study. In this test, all tests performed by using male mice, not female mice. There are some 
sex-mediated differences in opioid receptor expression and signaling, manifesting in 
differential effects in tests of analgesia in humans and rodents and important differences in 
rodent models of drug abuse and relapse (Becker & Chartoff, 2019; Craft, 2008; Dahan et 
al., 2008; Lee & Ho, 2013). The effect of the combination study may be different, if the 
other sex animal used. The animals housed in light/dark cycle, but experiment performed 
only in the light part. So, the inactive part of the mouse diurnal cycle may provide variable 
opioid receptor expression. (Mitchell et al. 1998) and opioid receptor activation can itself 
alter circadian rhythms (Pacesova et al. 2015; Webb et al. 2015).  If the tests performed in 
dark cycle, there is a possibility to get different results. In future research plan is to test 













Opioids are generally prescribed to treat pain but with prolonged use, the effects of 
pain-relieving effects may lessen. Gradually a patient may develop dependence as well as 
withdrawal symptoms, which leads to possible addiction. The opioid epidemic necessitates 
the development of new potent analgesics or analgesic combinations without or limited 
abuse liability. Our investigations into the novel analgesic IBNtxA and combinations of 
morphine and MP-III-024 represent two avenues that can provide new 
pharmacotherapeutics to meet this challenge. IBNtxA has been identified as a novel 
analgesic that has no addictive properties. New drug combinations of morphine and MP-
III-024 may provide synergistic effects. Isobolographic study played a crucial role in 
interpreting the potency of these combinations. In the future, other pharmacological 
properties, and pharmacokinetics of IBNtxA can be investigated. Combination of other 
GABA PAMs with Morphine or other Opioids, the safety profile of these combinations 
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